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Preamble
The American College of Cardiology (ACC) and the American Heart Association (AHA) are committed to the prevention and management of cardiovascular diseases through professional education and research for clinicians, providers, and patients. Since 1980, the ACC and AHA have shared a responsibility to translate scientific evidence into clinical practice guidelines (CPGs) with recommendations to standardize and improve cardiovascular health. These CPGs, based on systematic methods to evaluate and classify evidence, provide a cornerstone of quality cardiovascular care.
In response to published reports from the Institute of Medicine 1,2 and the ACC/AHA's mandate to evaluate new knowledge and maintain relevance at the point of care, the ACC/AHA Task Force on Practice Guidelines (Task Force) began modifying its methodology. This modernization effort is published in the 2012 Methodology Summit Report 3 and 2014 perspective article. 4 The latter recounts the history of the collaboration, changes over time, current policies, and planned initiatives to meet the needs of an evolving healthcare environment. Recommendations on value in proportion to resource utilization will be incorporated as high-quality comparative-effectiveness data become available. 5 The relationships between CPGs and data standards, appropriate use criteria, and performance measures are addressed elsewhere. 4 Intended Use-CPGs provide recommendations applicable to patients with or at risk of developing cardiovascular disease. The focus is on medical practice in the United States, but CPGs developed in collaboration with other organizations may have a broader target. Although CPGs may be used to inform regulatory or payer decisions, the intent is to improve quality of care and be aligned with the patient's best interest.
Evidence Review-Guideline writing committee (GWC) members are charged with reviewing the literature; weighing the strength and quality of evidence for or against particular tests, treatments, or procedures; and estimating expected health outcomes when data exist. In analyzing the data and developing CPGs, the GWC uses evidence-based methodologies developed by the Task Force. 6 A key component of the ACC/AHA CPG methodology is the development of recommendations on the basis of all available evidence. Literature searches focus on randomized controlled trials (RCTs) but also include registries, nonrandomized comparative and descriptive studies, case series, cohort studies, systematic reviews, and expert opinion. Only selected references are cited in the CPG. To ensure that CPGs remain current, new data are reviewed biannually by the GWCs and the Task Force to determine if recommendations should be updated or modified. In general, a target cycle of 5 years is planned for full revision. 1 The Task Force recognizes the need for objective, independent Evidence Review Committees (ERCs) to address key clinical questions posed in the PICOTS format (P=population; I=intervention; C=comparator; O=outcome; T=timing; S=setting). The ERCs include methodologists, epidemiologists, clinicians, and biostatisticians who systematically survey, abstract, and assess the quality of the evidence base. 3, 4 Practical considerations, including time and resource constraints, limit the ERCs to addressing key clinical questions for which the evidence relevant to the guideline topic lends itself to systematic review and analysis when the systematic review could impact the sense or strength of related recommendations. The GWC develops recommendations on the basis of the systematic review and denotes them with superscripted "SR" (ie, SR ) to emphasize support derived from formal systematic review.
Guideline-Directed Medical Therapy-Recognizing advances in medical therapy across the spectrum of cardiovascular diseases, the Task Force designated the term "guidelinedirected medical therapy" (GDMT) to represent recommended medical therapy as defined mainly by Class I measuresgenerally a combination of lifestyle modification and drugand device-based therapeutics. As medical science advances, GDMT evolves, and hence GDMT is preferred to "optimal medical therapy." For GDMT and all other recommended drug treatment regimens, the reader should confirm the dosage with product insert material and carefully evaluate for contraindications and possible drug interactions. Recommendations are limited to treatments, drugs, and devices approved for clinical use in the United States.
Class of Recommendation and Level of Evidence-Once recommendations are written, the Class of Recommendation (COR; ie, the strength the GWC assigns to the recommendation, which encompasses the anticipated magnitude and judged certainty of benefit in proportion to risk) is assigned by the GWC. Concurrently, the Level of Evidence (LOE) rates the scientific evidence supporting the effect of the intervention on the basis of the type, quality, quantity, and consistency of data from clinical trials and other reports ( Table 1) . 4 Relationships With Industry and Other Entities-The ACC and AHA exclusively sponsor the work of GWCs, without commercial support, and members volunteer their time for this activity. The Task Force makes every effort to avoid actual, potential, or perceived conflicts of interest that might arise through relationships with industry or other entities (RWI). All GWC members and reviewers are required to fully disclose current industry relationships or personal interests, from 12 months before initiation of the writing effort. Management of RWI involves selecting a balanced GWC and requires that both the chair and a majority of GWC members have no relevant RWI (see Appendix 1 for the definition of relevance). GWC members are restricted with regard to writing or voting on sections to which their RWI apply. In addition, for transparency, GWC members' comprehensive disclosure information is available as an online supplement. Comprehensive disclosure information for the Task Force is also available at http:// www.cardiosource.org/en/ACC/About-ACC/Who-We-Are/ Leadership/Guidelines-and-Documents-Task-Forces.aspx.
The Task Force strives to avoid bias by selecting experts from a broad array of backgrounds representing different geographic regions, genders, ethnicities, intellectual perspectives/biases, and scopes of clinical practice. Selected organizations and professional societies with related interests and expertise are invited to participate as partners or collaborators.
Individualizing Care in Patients With Associated Conditions and Comorbidities-The ACC and AHA recognize the complexity of managing patients with multiple conditions, compared with managing patients with a single disease, and the challenge is compounded when CPGs for evaluation or treatment of several coexisting illnesses are discordant or interacting. 7 CPGs attempt to define practices that meet the needs of patients in most, but not all, circumstances and do not replace clinical judgment.
Clinical Implementation-Management in accordance with CPG recommendations is effective only when followed; therefore, to enhance the patient's commitment to treatment and compliance with lifestyle adjustment, clinicians should engage the patient to participate in selecting interventions on the basis of the patient's individual values and preferences, taking associated conditions and comorbidities into consideration (eg, shared decision making). Consequently, there are circumstances in which deviations from these CPGs are appropriate.
The recommendations in this CPG are the official policy of the ACC and AHA until they are superseded by a published addendum, focused update, or revised full-text CPG. The reader is encouraged to consult the full-text CPG 8 for additional guidance and details about perioperative cardiovascular evaluation and noncardiac surgery, because the executive summary contains mainly the recommendations.
Jeffrey L. Anderson, MD, FACC, FAHA Chair, ACC/AHA Task Force on Practice Guidelines 1. Introduction
Methodology and Evidence Review
The recommendations listed in this CPG are, whenever possible, evidence based. In April 2013, an extensive evidence review was conducted, which included a literature review through July 2013. Other selected references published through May 2014 were also incorporated by the GWC. 
Scope of the CPG
The focus of this CPG is the perioperative cardiovascular evaluation and management of the adult patient undergoing noncardiac surgery. This includes preoperative risk assessment and cardiovascular testing, as well as (when indicated) perioperative pharmacological (including anesthetic) management and perioperative monitoring that includes devices and biochemical markers. This CPG is intended to inform all the medical professionals involved in the care of these patients. The preoperative evaluation of the patient undergoing noncardiac surgery can be performed for multiple purposes, including 1) assessment of perioperative risk (which can be used to inform the decision to proceed or the choice of surgery and which includes the patient's perspective), 2) determination of the need for changes in management, and 3) identification of cardiovascular conditions or risk factors requiring longer-term management. Changes in management can include the decision to change medical therapies, the decision to perform further cardiovascular interventions, or recommendations about postoperative monitoring. This may lead to recommendations and discussions with the perioperative team about the optimal location and timing of surgery (eg, ambulatory surgery center versus outpatient hospital, or inpatient admission) or alternative strategies.
The key to optimal management is communication among all of the relevant parties (ie, surgeon, anesthesiologist, primary caregiver, and consultants) and the patient. The goal of preoperative evaluation is to promote patient engagement and facilitate shared decision making by providing patients and their providers with clear, understandable information about perioperative cardiovascular risk in the context of the overall risk of surgery.
The Task Force has chosen to make recommendations about care management on the basis of available evidence from studies of patients undergoing noncardiac surgery. Extrapolation from data from the nonsurgical arena or cardiac surgical arena was made only when no other data were available and the benefits of extrapolating the data outweighed the risks.
During the initiation of the writing effort, concern was expressed by Erasmus University about the scientific integrity of studies led by Poldermans. 10 The GWC reviewed 2 reports from Erasmus University published on the Internet, 10,11 as well as other relevant articles on this body of scientific investigation. [12] [13] [14] The 2012 report from Erasmus University concluded that the conduct in the DECREASE (Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography) IV and V trials "was in several respects negligent and scientifically incorrect" and that "essential source documents are lacking" to make conclusions about other studies led by Poldermans. 10 Additionally, Erasmus University was contacted to ensure that the GWC had up-to-date information. On the basis of the published information, discussions between the Task Force and GWC leadership ensued to determine how best to treat any study in which Poldermans was the senior investigator (ie, either the first or last author). The Task Force developed the following framework for this document:
1. The ERC will include the DECREASE trials in the sensitivity analysis, but the systematic review report will be based on the published data on perioperative beta blockade, with data from all DECREASE trials excluded.
The DECREASE trials and other derivative studies by
Poldermans should not be included in the CPG data supplements and evidence tables. 3. If nonretracted DECREASE publications and/or other derivative studies by Poldermans are relevant to the topic, they can only be cited in the text with a comment about the finding compared with the current recommendation but should not form the basis of that recommendation or be used as a reference for the recommendation.
The Task Force and GWC believe that it is crucial for the sake of transparency to include the nonretracted publications in the text of the document. This is particularly important because further investigation is occurring simultaneously with deliberation of the CPG recommendations. Because of the availability of new evidence and the international impact of the controversy about the DECREASE trials, the ACC/AHA and European Society of Cardiology/European Society of Anesthesiology began revising their respective CPGs concurrently. The respective GWCs performed their literature reviews and analyses independently and then developed their recommendations. Once peer review of both CPGs was completed, the GWCs chose to discuss their respective recommendations for beta-blocker therapy and other relevant issues. Any differences in recommendations were discussed and clearly articulated in the text; however, the GWCs aligned a few recommendations to avoid confusion within the clinical community, except where international practice variation was prevalent.
In developing this CPG, the GWC reviewed prior published CPGs and related statements. Table 2 lists these publications and statements deemed pertinent to this effort and is intended for use as a resource. However, because of the availability of new evidence, the current CPG may include recommendations that supersede those previously published.
Definitions of Urgency and Risk
In describing the temporal necessity of operations in this CPG, the GWC developed the following definitions by consensus. An emergency procedure is one in which life or limb is threatened if not in the operating room, where there is time for no or very limited or minimal clinical evaluation, typically within <6 hours. An urgent procedure is one in which there may be time for a limited clinical evaluation, usually when life or limb is threatened if December 9/16, 2014 not in the operating room, typically between 6 and 24 hours. A time-sensitive procedure is one in which a delay of >1 to 6 weeks to allow for an evaluation and significant changes in management will negatively affect outcome. Most oncologic procedures would fall into this category. An elective procedure is one in which the procedure could be delayed for up to 1 year. Individual institutions may use slightly different definitions, but this framework could be mapped to local categories. A low-risk procedure is one in which the combined surgical and patient characteristics predict a risk of a major adverse cardiac event (MACE) of death or myocardial infarction (MI) of <1%. Selected examples of low-risk procedures include cataract and plastic surgery. 35, 36 Procedures with a risk of MACE of ≥1% are considered elevated risk. Many previous risk-stratification schema have included intermediate-and high-risk classifications. Because recommendations for intermediate-and high-risk procedures are similar, classification into 2 categories simplifies the recommendations without loss of fidelity. Additionally, a risk calculator has been developed that allows more precise calculation of surgical risk, which can be incorporated into perioperative decision making. 37 Approaches to establishing low and elevated risk are developed more fully in Section 3 in the full-text CPG.
Clinical Risk Factors: Recommendations

Valvular Heart Disease
See the 2014 valvular heart disease CPG for the complete set of recommendations and specific definitions of disease severity. 16 Class I 1. It is recommended that patients with clinically suspected moderate or greater degrees of valvular 
Other Clinical Risk Factors
Stepwise Approach to Perioperative Cardiac Assessment: Treatment Algorithm
See Figure 1 for a stepwise approach to perioperative cardiac assessment for CAD.
The GWC developed an algorithmic approach to perioperative cardiac assessment on the basis of the available evidence and expert opinion, the rationale of which is outlined throughout the CPG. The algorithm incorporates the perspectives of clinicians caring for the patient to provide informed consent and help guide perioperative management to minimize risk. It is also crucial to incorporate the patient's perspective with regard to the assessment of the risk of surgery or alternative therapy and the risk of any GDMT or coronary and valvular interventions before noncardiac surgery. Patients may elect to forgo a surgical intervention if the risk of perioperative morbidity and mortality is extremely high; soliciting this information from the patient before surgery is a key part of shared decision making.
Supplemental Preoperative Evaluation: Recommendations
See Table 3 for a summary of recommendations for supplemental preoperative evaluation.
The 12-Lead Electrocardiogram
Class IIa
Preoperative resting 12-lead electrocardiogram (ECG)
is reasonable for patients with known coronary heart disease, significant arrhythmia, peripheral arterial disease, cerebrovascular disease, or other significant structural heart disease, except for those undergoing low-risk surgery. 64 Table 1 .
Step 1: In patients scheduled for surgery with risk factors for or known CAD, determine the urgency of surgery. If an emergency, then determine the clinical risk factors that may influence perioperative management and proceed to surgery with appropriate monitoring and management strategies based on the clinical assessment (see Section 2.5 in the full-text CPG for more information on CAD). (For patients with symptomatic HF, VHD, or arrhythmias, see Sections 2.2, 2.4, and 2.5 in the full-text CPG for information on evaluation and management.) Step 2: If the surgery is urgent or elective, determine if the patient has an ACS. If yes, then refer patient for cardiology evaluation and management according to GDMT according to the UA/NSTEMI and STEMI CPGs. 19, 21 Step 3: If the patient has risk factors for stable CAD, then estimate the perioperative risk of MACE on the basis of the combined clinical/surgical risk. This estimate can use the American College of Surgeons NSQIP risk calculator (http:// www.riskcalculator.facs.org) or incorporate the RCRI 62 with an estimation of surgical risk. For example, a patient undergoing very low-risk surgery (eg, ophthalmologic surgery), even with multiple risk factors, would have a low risk of MACE, whereas a patient undergoing major vascular surgery with few risk factors would have an elevated risk of MACE (see Section 3 in the full-text CPG).
Step 4: If the patient has a low risk of MACE (<1%), then no further testing is needed, and the patient may proceed to surgery (Section 3 in the full-text CPG).
Step 5: If the patient is at elevated risk of MACE, then determine functional capacity with an objective measure or scale such as the DASI. 63 If the patient has moderate, good, or excellent functional capacity (≥4 METs), then proceed to surgery without further evaluation (Section 4.1 in the full-text CPG).
Step 6: If the patient has poor (<4 METs) or unknown functional capacity, then the clinician should consult with the patient and perioperative team to determine whether further testing will impact patient decision making (eg, decision to perform original surgery or willingness to undergo CABG or PCI, depending on the results of the test) or perioperative care. If yes, then pharmacological stress testing is appropriate. In those patients with unknown functional capacity, exercise stress testing may be reasonable to perform. If the stress test is abnormal, consider coronary angiography and revascularization depending on the extent of the abnormal test. The patient can then proceed to surgery with GDMT or consider alternative strategies, such as noninvasive treatment of the indication for surgery (eg, radiation therapy for cancer) or palliation. If the test is normal, proceed to surgery according to GDMT (Section 4.3).
Step 7: If testing will not impact decision making or care, then proceed to surgery according to GDMT or consider alternative strategies, such as noninvasive treatment of the indication for surgery (eg, radiation therapy for cancer) or palliation. ACS indicates acute coronary syndrome; CABG, coronary artery bypass graft; CAD, coronary artery disease; CPG, clinical practice guideline; DASI, Duke Activity Status Index; GDMT, guideline-directed medical therapy; HF, heart failure; MACE, major adverse cardiac event; MET, metabolic equivalent; NB, No Benefit; NSQIP, National Surgical Quality Improvement Program; PCI, percutaneous coronary intervention; RCRI, Revised Cardiac Risk Index; STEMI, ST-elevation myocardial infarction; UA/NSTEMI, unstable angina/non-ST-elevation myocardial infarction; and VHD, valvular heart disease. 
Perioperative Therapy: Recommendations
See Table 4 for a summary of recommendations for perioperative therapy.
Coronary Revascularization Before Noncardiac Surgery
Class I 1. Revascularization before noncardiac surgery is recommended in circumstances in which revascularization is indicated according to existing CPGs. 95, 96 (Level of Evidence: C) (See Table A in Appendix 3 for related recommendations.)
Class III: No Benefit
1. It is not recommended that routine coronary revascularization be performed before noncardiac surgery exclusively to reduce perioperative cardiac events. 97 
(Level of Evidence: B)
Patients undergoing risk stratification surgery before elective noncardiac procedures and whose evaluation recommends coronary artery bypass graft surgery should undergo coronary revascularization before an elevated-risk surgical procedure. 98 The cumulative mortality and morbidity risks of both the coronary revascularization procedure and the noncardiac surgery should be weighed carefully in light of the individual patient's overall health, functional status, and prognosis. The indications for preoperative surgical coronary revascularization are identical to those recommended in the 2011 coronary artery bypass graft surgery CPG and the 2011 percutaneous coronary intervention (PCI) CPG and the accumulated data on which those conclusions were based. 95,96 (See Table A in Appendix 3 for the related recommendations.)
The role of preoperative PCI in reducing untoward perioperative cardiac complications is uncertain given the available data. Performing PCI before noncardiac surgery should be limited to 1) patients with left main disease whose comorbidities preclude bypass surgery without undue risk and 2) patients with unstable coronary artery disease who would be appropriate candidates for emergency or urgent revascularization. 95, 96 Patients with ST-elevation MI or non-ST-elevation acute coronary syndrome benefit from early invasive management. 96 In such patients, in whom noncardiac surgery is time sensitive despite an increased risk in the perioperative period, a strategy of balloon angioplasty or bare-metal stent (BMS) implantation should be considered.
Timing of Elective Noncardiac Surgery in Patients With Previous PCI
Class I
Elective noncardiac surgery should be delayed 14 days after balloon angioplasty (Level of Evidence: C) and 30 days after BMS implantation. 99-101 (Level of Evidence B) 2. Elective noncardiac surgery should optimally be delayed 365 days after drug-eluting stent (DES) implantation. 102-105 (Level of Evidence: B)
In patients in whom noncardiac surgery is required, a consensus decision among treating clinicians as to the relative risks of surgery and discontinuation or continuation of antiplatelet therapy can be useful. (Level of Evidence: C)
Class IIb* 
Elective noncardiac surgery after DES implantation may be considered after 180 days if the risk of further
Perioperative Beta-Blocker Therapy
See the ERC systematic review report, "Perioperative Beta Blockade in Noncardiac Surgery: A Systematic Review for the 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery" for the complete evidence review on perioperative beta-blocker therapy. 9 These recommendations have been designated with a SR to emphasize the rigor of support from the ERC's systematic review.
As noted in the Scope of this CPG (Section 1.4) , the recommendations in Section 5.3 are based on a separately commissioned review of the available evidence, the results of which were used to frame our decision making. Full details are provided in the ERC's systematic review report 9 and data supplements. However, 3 key findings were powerful influences on this CPG's recommendations:
1. The systematic review suggests that preoperative use of beta blockers was associated with a reduction in cardiac events in the studies examined, but few data support the effectiveness of preoperative administration of beta blockers to reduce risk of surgical death. 2. Consistent and clear associations exist between betablocker administration and adverse outcomes, such as bradycardia and stroke. 3. These findings were quite consistent even when the DECREASE studies 108, 109 in question or POISE (Perioperative Ischemic Evaluation Study) 110 were excluded. Stated alternatively, exclusion of these studies did not substantially affect estimates of risk or benefit. reasonable to begin beta blockers before surgery. 117 
Class I
Beta blockers should be continued in patients undergoing surgery who have been on beta blockers chronically. 111-117 (Level of Evidence: B) SR
Class
(Level of Evidence: B) SR In patients with a compelling long-term indication for beta-blocker therapy but no other RCRI risk factors, initiating beta blockers in the perioperative setting as
an approach to reduce perioperative risk is of uncertain benefit. 111,117,120 (Level of Evidence: B) SR 2. In patients in whom beta-blocker therapy is initiated, it may be reasonable to begin perioperative beta blockers long enough in advance to assess safety and tolerability, preferably more than 1 day before surgery. 110 Table B in Appendix 3 for applicable recommendations from the 2011 secondary prevention CPG). 124 This recommendation is consistent with the Surgical Care Improvement Project National Measures (CARD-2) as of November 2013. 125 Particular attention should be paid to the need to modify or temporarily discontinue beta blockers as clinical circumstances (eg, hypotension, bradycardia, 126 bleeding) 118 dictate. The risks and benefits of perioperative beta blocker use appear to be favorable in patients who have intermediate-or high-risk myocardial ischemia noted on preoperative stress testing. 119, 127 The decision to begin beta blockers should be influenced by whether a patient is at risk for stroke [128] [129] [130] and whether the patient has other relative contraindications (such as uncompensated HF). Observational data suggest that patients appear to benefit from use of beta blockers in the perioperative setting if they have ≥3 RCRI risk factors. It may be reasonable to begin beta blockers long enough in advance of the operative date that clinical effectiveness and tolerability can be assessed. 110, [121] [122] [123] Starting the medication 2 to 7 days before surgery may be preferred, but few data support the need to start beta blockers >30 days beforehand. [121] [122] [123] 
Perioperative Statin Therapy
Statins should be continued in patients currently
taking statins and scheduled for noncardiac surgery. 131 
Antiplatelet Agents
Please see Figure 2 for an algorithm for antiplatelet management in patients with PCI and noncardiac surgery. 
Anesthetic Consideration and Intraoperative Management: Recommendations
See Table 5 for a summary of recommendations for anesthetic consideration and intraoperative management.
Choice of Anesthetic Technique and Agent
Class IIa 1. Use of either a volatile anesthetic agent or total intravenous anesthesia is reasonable for patients undergoing noncardiac surgery, and the choice is determined by factors other than the prevention of myocardial ischemia and MI. 146 Table 1 . *Assuming patient is currently on DAPT. ASA indicates aspirin; ASAP, as soon as possible; BMS, baremetal stent; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; and PCI, percutaneous coronary intervention.
Neuraxial anesthesia for postoperative pain relief can be effective in patients undergoing abdominal aortic surgery to decrease the incidence of perioperative MI. 148 (Level of Evidence: B)
Class IIb 1. Perioperative epidural analgesia may be considered to decrease the incidence of preoperative cardiac events in patients with a hip fracture. 149 (Level of Evidence: B)
Intraoperative Management
The emergency use of perioperative transesophageal echocardiogram is reasonable in patients with hemodynamic instability undergoing noncardiac surgery to determine the cause of hemodynamic instability when it persists despite attempted corrective therapy, if expertise is readily available. (Level of Evidence: C)
Class IIb 
Maintenance of normothermia may be reasonable to reduce perioperative cardiac events in patients under
Future Research Directions
Current recommendations for perioperative cardiovascular evaluation and management for noncardiac surgery are based largely on clinical experience and observational studies, with few prospective RCTs. The GWC recommends that future research on perioperative evaluation and management span the spectrum from RCTs to regional and national registries to focus on patient outcomes. Diagnostic cardiovascular testing continues to evolve, with newer imaging modalities being developed, such as coronary calcium scores, computed tomography angiography, and cardiac magnetic resonance imaging. The value of these modalities in preoperative screening is uncertain and warrants further study.
The use of perioperative beta blockers in beta-blocker-naïve patients undergoing noncardiac surgery remains controversial because of uncertainty about the following issues: 1) optimal duration for the initiation of beta blockers before elective noncardiac surgery; 2) optimal dosing and titration protocol perioperatively to avoid hemodynamic instability, including hypotension and bradycardia; and 3) which elevated-risk patient subsets would benefit the most from initiation of perioperative beta blocker. RCTs are needed to demonstrate when to start beta-blocker therapy before noncardiac surgery, the optimal type and dose, and titration protocol.
The evidence base for the predictive value of biomarkers in the perioperative period has grown. However, the utility of this information in influencing management and outcome is unknown and is currently undergoing investigation. The results of these investigations could lead to changes in recommendations in the future.
To implement the recommendations of the current perioperative CPGs effectively, a "perioperative team approach" is needed. The perioperative team is intended to engage clinicians with appropriate expertise; enhance communication of the benefits, risks, and alternatives; and include the patient's preferences, values, and goals. Future research will also be needed to understand how information on perioperative risk is incorporated into patient decision making. 
